CPRX – Catalyst Pharmaceuticals, Inc.
CPRX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
7.14
Margin Of Safety %
-3
Put/Call OI Ratio
0.33
EPS Next Q Diff
0.29
EPS Last/This Y
1.11
EPS This/Next Y
0.28
Price
31.14
Target Price
32.62
Analyst Recom
2.5
Performance Q
28.31
Upside
95.6%
Beta
0.73
Ticker: CPRX
20 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-13 | CPRX | 25.35 | 0.89 | 0.09 | 8674 |
| 2026-04-14 | CPRX | 26.18 | 0.89 | 0.02 | 8665 |
| 2026-04-15 | CPRX | 25.84 | 0.66 | 0.13 | 10403 |
| 2026-04-17 | CPRX | 26.34 | 0.62 | 0.14 | 10879 |
| 2026-04-20 | CPRX | 26.07 | 0.64 | 0.15 | 8073 |
| 2026-04-21 | CPRX | 25.64 | 0.62 | 0.46 | 8348 |
| 2026-04-23 | CPRX | 27.68 | 0.62 | 0.01 | 9251 |
| 2026-04-24 | CPRX | 27.38 | 0.49 | 0.00 | 10810 |
| 2026-04-27 | CPRX | 29.26 | 0.42 | 0.05 | 12027 |
| 2026-04-28 | CPRX | 29.43 | 0.37 | 0.27 | 13447 |
| 2026-04-29 | CPRX | 28.26 | 0.37 | 0.32 | 13581 |
| 2026-04-30 | CPRX | 28.14 | 0.38 | 0.02 | 13420 |
| 2026-05-01 | CPRX | 28.73 | 0.38 | 0.02 | 13337 |
| 2026-05-04 | CPRX | 28.92 | 0.38 | 0.13 | 13371 |
| 2026-05-05 | CPRX | 30.86 | 0.38 | 0.01 | 13356 |
| 2026-05-06 | CPRX | 30.52 | 0.37 | 0.12 | 13625 |
| 2026-05-07 | CPRX | 31.16 | 0.37 | 0.08 | 13693 |
| 2026-05-08 | CPRX | 31.16 | 0.35 | 0.14 | 14446 |
| 2026-05-11 | CPRX | 31.15 | 0.36 | 0.06 | 14081 |
| 2026-05-12 | CPRX | 31.14 | 0.33 | 0.21 | 15230 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
20 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-13 | CPRX | 25.34 | -6.6 | 28.2 | 2.85 |
| 2026-04-14 | CPRX | 26.18 | -6.6 | 34.7 | 2.85 |
| 2026-04-15 | CPRX | 25.84 | -6.6 | 17.6 | 2.85 |
| 2026-04-16 | CPRX | 25.88 | -6.6 | 22.8 | 2.85 |
| 2026-04-17 | CPRX | 26.28 | -6.6 | 27.8 | 2.85 |
| 2026-04-20 | CPRX | 26.08 | -6.6 | 19.9 | 2.85 |
| 2026-04-21 | CPRX | 25.64 | -6.6 | 16.4 | 2.85 |
| 2026-04-22 | CPRX | 25.94 | -6.6 | 26.7 | 2.85 |
| 2026-04-23 | CPRX | 27.69 | -6.6 | 46.7 | 2.85 |
| 2026-04-24 | CPRX | 27.37 | -6.6 | 18.3 | 2.85 |
| 2026-04-27 | CPRX | 29.27 | -6.6 | 47.1 | 2.85 |
| 2026-04-28 | CPRX | 29.43 | -6.6 | 24.3 | 2.85 |
| 2026-04-30 | CPRX | 28.12 | -6.6 | 20.7 | 2.85 |
| 2026-05-01 | CPRX | 28.72 | -6.6 | 29.8 | 2.85 |
| 2026-05-04 | CPRX | 28.92 | -6.6 | 24.6 | 2.85 |
| 2026-05-05 | CPRX | 30.87 | -5.5 | 45.7 | 2.86 |
| 2026-05-06 | CPRX | 30.51 | -5.5 | 18.3 | 2.86 |
| 2026-05-07 | CPRX | 31.17 | -5.5 | 29.8 | 2.86 |
| 2026-05-08 | CPRX | 31.16 | -5.5 | 22.5 | 2.86 |
| 2026-05-11 | CPRX | 31.14 | -5.5 | 22.2 | 2.86 |
| 2026-05-12 | CPRX | 31.14 | -5.5 | 22.4 | 2.86 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
21 items
«
‹
Current Page1 of 1
›
»
22 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-13 | CPRX | -0.30 | 1.36 | 8.32 |
| 2026-04-14 | CPRX | -0.30 | 1.36 | 8.32 |
| 2026-04-15 | CPRX | -0.30 | 1.36 | 8.32 |
| 2026-04-16 | CPRX | -0.30 | 1.36 | 8.32 |
| 2026-04-17 | CPRX | -0.30 | 1.36 | 8.32 |
| 2026-04-20 | CPRX | -0.30 | 1.16 | 8.32 |
| 2026-04-21 | CPRX | -0.30 | 1.16 | 8.32 |
| 2026-04-22 | CPRX | -0.30 | 1.16 | 8.32 |
| 2026-04-23 | CPRX | -0.30 | 1.16 | 8.33 |
| 2026-04-24 | CPRX | -0.30 | 1.16 | 8.33 |
| 2026-04-27 | CPRX | -0.30 | 1.19 | 7.75 |
| 2026-04-28 | CPRX | -0.30 | 1.19 | 7.75 |
| 2026-04-29 | CPRX | -0.30 | 1.19 | 7.75 |
| 2026-04-30 | CPRX | -0.30 | 1.19 | 7.75 |
| 2026-05-01 | CPRX | -0.30 | 1.19 | 7.75 |
| 2026-05-04 | CPRX | -0.30 | 1.31 | 7.75 |
| 2026-05-05 | CPRX | -0.30 | 1.31 | 7.75 |
| 2026-05-06 | CPRX | -0.30 | 1.31 | 7.75 |
| 2026-05-07 | CPRX | -0.30 | 1.31 | 7.73 |
| 2026-05-08 | CPRX | -0.30 | 1.31 | 7.73 |
| 2026-05-11 | CPRX | -0.30 | 1.74 | 7.73 |
| 2026-05-12 | CPRX | -0.30 | 1.74 | 7.14 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
22 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
0.4
Avg. EPS Est. Current Quarter
0.64
Avg. EPS Est. Next Quarter
0.69
Insider Transactions
-0.3
Institutional Transactions
1.74
Beta
0.73
Average Sales Estimate Current Quarter
147
Average Sales Estimate Next Quarter
153
Fair Value
30.2
Quality Score
92
Growth Score
98
Sentiment Score
82
Actual DrawDown %
4.4
Max Drawdown 5-Year %
-45.4
Target Price
32.62
P/E
17.9
Forward P/E
13.9
PEG
1.39
P/S
6.38
P/B
3.76
P/Free Cash Flow
18.31
EPS
1.74
Average EPS Est. Cur. Y
2.86
EPS Next Y. (Est.)
3.14
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
37.08
Relative Volume
1.88
Return on Equity vs Sector %
-4.4
Return on Equity vs Industry %
11.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
22.4
◆
CPRX
Healthcare
$31.14
📉
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
2/20
Pullback
8/25
Volume
0/15
Valuation
6/20
TP/AR
1/10
Options
8/10
RSI
73.2
Range 1M
82.2%
Sup Dist
0%
🚀
Momentum Growth
Ride accelerating trends
WEAK
Momentum
13/25
Growth
13/30
Estimates
6/20
Inst/Vol
10/15
Options
8/10
EPS Yr
14.4%
EPS NY
16.5%
52W%
89.6%
💎
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+126.5% upside
Quality
25/30
Valuation
19/30
Growth
11/25
Stability
8/10
LT Trend
1/5
Upside
+126.5%
Quality
92
MoS
-3%
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 182
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
CPRX
Latest News
—
Caricamento notizie per CPRX…
stock quote shares CPRX – Catalyst Pharmaceuticals, Inc. Stock Price stock today
news today CPRX – Catalyst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CPRX – Catalyst Pharmaceuticals, Inc. yahoo finance google finance
stock history CPRX – Catalyst Pharmaceuticals, Inc. invest stock market
stock prices CPRX premarket after hours
ticker CPRX fair value insiders trading